RBC Trims Becton Dickinson (BDX) Outlook despite Stable MedTech Demand

Becton, Dickinson and Company (NYSE:BDX) is included among the 10 Healthcare Stocks with Highest Dividends.

On April 14, RBC Capital lowered its price recommendation on Becton, Dickinson and Company (NYSE:BDX) to $175 from $195. It maintained a Sector Perform rating on the shares. The update came as part of a broader Q1 preview for MedTech names. The firm said its intra-quarter due diligence points to strong fundamentals and stable end markets. It does not see any signs of demand disruption at this stage.RBC also said the recent sentiment-driven dislocation looks unwarranted. In its view, this is creating opportunities across the sector, both heading into Q1 earnings and over the longer term.

For Becton Dickinson, though, the firm expects the stock to remain range-bound. It pointed to the lack of a clear catalyst, while noting that Alaris is likely to remain a headwind in FY26 and FY27.

Becton, Dickinson and Company (NYSE:BDX) is a global medical technology company. It develops, manufactures, and sells a wide range of medical supplies, devices, laboratory equipment, and diagnostic products used by healthcare institutions, physicians, life science researchers, and clinical laboratories.

READ NEXT: 14 Value Stocks with Highest Dividends and Early Retirement Portfolio: Top 15 Stocks to Buy

Disclosure: None. Follow Insider Monkey on Google News.